The prognostic impact of SIGLEC5-induced impairment of CD8+ T cell activation in sepsis
eBioMedicine · 2023
DOI: 10.1016/j.ebiom.2023.104841 ↗Kurz gefasst
Fachartikel in der Zeitschrift eBioMedicine, 2023. Verfasst von Roberto Lozano-Rodríguez und 19 weiteren Autor:innen. Beteiligte Einrichtung: The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Paseo de la Castellana 261, Madrid 28046, Spain; Tumour Immunology Laboratory, …. Hauptthemen laut MEDLINE: Sepsis. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Federación Española de Enfermedades Raras, Instituto de Salud Carlos III, Horizon 2020.
Themen: Sepsis
Abstract (Originalsprache)
BACKGROUND: Sepsis is associated with T-cell exhaustion, which significantly reduces patient outcomes. Therefore, targeting of immune checkpoints (ICs) is deemed necessary for effective sepsis management. Here, we evaluated the role of SIGLEC5 as an IC ligand and explored its potential as a biomarker for sepsis. METHODS: In vitro and in vivo assays were conducted to both analyse SIGLEC5's role as an IC ligand, as well as assess its impact on survival in sepsis. A multicentre prospective cohort study was conducted to evaluate the plasmatic soluble SIGLEC5 (sSIGLEC5) as a mortality predictor in the first 60 days after admission in sepsis patients. Recruitment included sepsis patients (n = 346), controls with systemic inflammatory response syndrome (n = 80), aneurism (n = 11), stroke (n = 16), and healthy volunteers (HVs, n = 100). FINDINGS: SIGLEC5 expression on monocytes was increased by HIF1α and was higher in septic patients than in healthy volunteers after ex vivo LPS challenge. Furthermore, SIGLEC5-PSGL1 interaction inhibited CD8+ T-cell proliferation. Administration of sSIGLEC5r (0.8 mg/kg) had adverse effects in mouse endotoxemia models. Additionally, plasma sSIGLEC5 levels of septic patients were higher than HVs and ROC analysis revealed it as a mortality marker with an AUC of 0.713 (95% CI, 0.656-0.769; p < 0.0001). Kaplan-Meier survival curve showed a significant decrease in survival above the calculated cut-off (HR of 3.418, 95% CI, 2.380-4.907, p < 0.0001 by log-rank test) estimated by Youden Index (523.6 ng/mL). INTERPRETATION: SIGLEC5 displays the hallmarks of an IC ligand, and plasma levels of sSIGLEC5 have been linked with increased mortality in septic patients. FUNDING: Instituto de Salud Carlos III (ISCIII) and "Fondos FEDER" to ELC (PIE15/00065, PI18/00148, PI14/01234, PI21/00869), CDF (PI21/01178), RLR (FI19/00334) and JAO (CD21/00059).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Paseo de la Castellana 261, Madrid 28046, Spain; Tumour Immunology Laboratory, IdiPAZ, La Paz University Hospital, Paseo de la Castellana 261, Madrid…
- Intensive Care Department, Vall d'Hebron University Hospital, Organ Dysfunction and Resuscitation Research Group, Vall d'Hebron Institute of Research and Medicine Department, Universitat Autònoma de Barcelona, Passeig d…
- Emergency Department, La Paz University Hospital, Paseo de la Castellana 261, Madrid 28046, Spain.
- The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Paseo de la Castellana 261, Madrid 28046, Spain; Emergency Department, La Paz University Hospital, Paseo de la Castellana 261, Madrid 28046, Spain.
- Microbiology Department, Vall d'Hebron University Hospital and Departament de Genètica i Microbiologia, Universitat Autònoma de Barcelona, Passeig de la Vall d'Hebron, 119, Barcelona 08035, Spain.
- Microbiology Department, Vall d'Hebron University Hospital and Faculty of Health Sciences, University of Vic - Central University of Catalonia (UVic-UCC), Manresa, Spain.
Förderung
- Federación Española de Enfermedades Raras
- Instituto de Salud Carlos III
- Horizon 2020
- Horizon 2020 Framework Programme
- European Regional Development Fund
- Catherine Donnelly Foundation
- European Commission
Zitieren
APA
Lozano-Rodríguez, R., Avendaño-Ortíz, J., Montalbán-Hernández, K., Ruiz-Rodríguez, J. C., Ferrer, R., Martín-Quirós, A., Maroun-Eid, C., González-López, J. J., Fàbrega, A., Terrón-Arcos, V., Gutiérrez-Fernández, M., Alonso-López, E., Cubillos-Zapata, C., Fernández-Velasco, M., Pérez de Diego, R., Pelegrin, P., García-Palenciano, C., Cueto, F. J., Del Fresno, C., & López-Collazo, E. (2023). The prognostic impact of SIGLEC5-induced impairment of CD8+ T cell activation in sepsis. eBioMedicine. https://doi.org/10.1016/j.ebiom.2023.104841
Vancouver
Lozano-Rodríguez R, Avendaño-Ortíz J, Montalbán-Hernández K, Ruiz-Rodríguez JC, Ferrer R, Martín-Quirós A, et al. The prognostic impact of SIGLEC5-induced impairment of CD8+ T cell activation in sepsis. eBioMedicine. 2023. doi:10.1016/j.ebiom.2023.104841
BibTeX
@article{LozanoRodrguez2023,
author = {Lozano-Rodríguez, Roberto and Avendaño-Ortíz, José and Montalbán-Hernández, Karla and Ruiz-Rodríguez, Juan Carlos and Ferrer, Ricardo and Martín-Quirós, Alejandro and Maroun-Eid, Charbel and González-López, Juan José and Fàbrega, Anna and Terrón-Arcos, Verónica and Gutiérrez-Fernández, María and Alonso-López, Elisa and Cubillos-Zapata, Carolina and Fernández-Velasco, María and Pérez de Diego, Rebeca and Pelegrin, Pablo and García-Palenciano, Carlos and Cueto, Francisco J and Del Fresno, Carlos and López-Collazo, Eduardo},
title = {The prognostic impact of SIGLEC5-induced impairment of CD8+ T cell activation in sepsis},
journal = {eBioMedicine},
year = {2023},
doi = {10.1016/j.ebiom.2023.104841}
}
EUVIMED